Researchers analyzed results from six phase III clinical trials involving 3,518 adults living with HIV-1. They compared a two-drug regimen consisting of doravirine and islatravir against the standard triple option therapy. The study focused on how well these treatments kept the virus under control and maintained immune cell counts.
The results showed that patients taking the doravirine and islatravir combination had a significantly lower risk of virological failure compared to those on the standard triple therapy. While both treatment groups achieved similar levels of viral suppression, the study noted specific differences in immune health based on dosage. Specifically, one higher dose formulation showed declines in CD4 cell counts at 48 weeks, while the optimized lower dose did not.
In terms of safety, the doravirine and islatravir combination was generally well-tolerated by patients. There were no significant differences in serious side effects or treatment dropouts between the two groups. Because this analysis is based on a specific set of trials, longer follow-up studies are still needed to confirm long-term immune safety. Talk with your doctor to see if this regimen fits your specific health needs.
